Fig 2: Elraglusib enhances immune cell tumor-infiltration to prolong survival in combination with anti-PD-L1 therapy in a syngeneic murine model of MSS colon carcinoma.(A) Experimental model overview of the syngeneic murine colon carcinoma BALB/c murine model using MSS cell line CT-26. (B) Kaplan–Meier estimator curves for all treatment groups as indicated. Statistical significance was determined using a Log-rank (Mantel-Cox) test. (C) Overview of cell lineage markers used for flow cytometric immunophenotyping analysis. 14-days post-treatment initiation immune cell subpopulations were analyzed in the spleen and tumor. (D) Splenic T cells, (E) Tumor-infiltrating T cells, (F) Splenic NK cells, and (G) Tumor-infiltrating NK cells were compared between responders (R, n=3) and non-responders (NR, n=18). NK cell subsets based on the expression of CD11b and CD27 were compared in the spleen and visualized via (H) bar graph and (I) pie chart. NK cell subsets based on the expression of CD11b and CD27 were also compared in the tumor and visualized via (J) bar graph and (K) pie chart. T cell ratios were compared in the (L) Spleen and (M) Tumor. Statistical significance was determined using two-tailed unpaired T tests. P-value legend: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Fig 3: Elraglusib enhances immune-cell tumor-infiltration to prolong survival in combination with anti-PD-L1 therapy in a syngeneic murine model of MSS colon carcinoma. (A) Experimental model overview of the syngeneic murine colon carcinoma BALB/c murine model using MSS cell line CT-26. (B) Kaplan-Meier estimator curves for all treatment groups as indicated. Statistical significance was determined using a Log-rank (Mantel-Cox) test. (C) Overview of cell lineage markers used for flow cytometric immunophenotyping analysis. Two weeks after treatment initiation, immune cell subpopulations were analyzed in the spleen and tumor. (D) Splenic T cells, (E) tumor-infiltrating T cells, (F) splenic NK cells, and (G) tumor-infiltrating NK cells were compared between responders (R, N = 3) and non-responders (NR, N = 18), regardless of treatment group. NK cell subsets based on the expression of CD11b and CD27 were compared in the spleen and visualized via (H) bar graph and (I) pie chart. NK cell subsets based on the expression of CD11b and CD27 were also compared in the tumor and visualized via (J) bar graph and (K) pie chart. T cell ratios were compared in the (L) Spleen and (M) Tumor. Statistical significance was determined using two-tailed unpaired T tests. p-value legend: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. ns: non-significant.